The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Investigator: Dean Foster Wong
Project Title: Comparison of Two Next Generation Tau Radiopharmaceuticals in Alzheimer’s Disease
Date: April 13, 2020
Request ID: S2001
Aim 1: Aim 1 To directly compare kinetics of 2nd generation Tau radioligand [F18]RO948 & [F18]MK6240 radioligands in the same older cognitively-normal control (OC) subjects and in clinically diagnosed Alzheimer�s Disease (AD) patients.
Aim 2: Aim 2 To examine whether these 2nd generation radioligands are free of off-target binding in the basal ganglia, thalamus & choroid plexus.
Aim 3: .
Investigator: Cyrus A. Raji, MD, PhD
Project Title: Neuroinflammatory and Alzheimer’s Disease Imaging Biomarkers in Obesity
Date: December 11, 2019
Request ID: S1904
Aim 1: Aim 1: To determine the presence of neurodegeneration in MAOO compared to MNOO and control (normal BMI < 25) groups amongst cognitively normal participants in the Knight ADRC. We will define minimum criteria for MAOO of BMI 25 and HbA1c of 5.7, MNOO with BMI 25 and HbA1c < 5.7%
Aim 2: Aim 2: To determine differences between MAOO and MNOO in MR imaging and PET biomarkers of neuroinflammation. Characterizing neuroinflammation on MR imaging will be done using DBSI.
Aim 3: Aim 3: Comparison in MAOO versus MNOO in cognitively normal controls on imaging biomarkers of AD pathology with amyloid and tau PET.
Investigator: Ganesh Babulal
Project Title: Dynamic models of successful aging and perceptions of AD risk among African Americans and Caucasians
Date: October 1, 2019
Request ID: S1903
Aim 1: Use Group Model Building to examine definitions of successful aging among African American and Caucasian older adults
Aim 2: Assess perceptions of AD risk on racial groups using system dynamics
Aim 3: Investigate how well being and quality of life of older adults in St Louis are impacted by perceptions of AD risk
Investigator: Michael Weiner
Project Title: BHR Validation of Online Methods to Predict & Monitor Cognitive Decline
Date: March 26, 2019
Request ID: S1902
Aim 1: Use IRT to develop an electonic version of the CDR based on historical ISP data
Aim 2: Refine and pilot test online version of CDR and Financial Capacity Inventory
Aim 3: Validate both eCDR and eFCI in clinical cohort combining in-person CAs and online collection
Investigator: Musiek; Holtzman; Ju
Project Title: Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
Date: March 7, 2019
Request ID: S1901
Aim 1: Investigate the bi-directional relationships between sleep, circadian fragmentation and AD pathogenesis in humans
Investigator: Dr. Randall Bateman
Project Title: Evaluation of plasma tau and p-tau quantitation by mass spectrometry as biomarkers for differential diagnosis of AD and tauopathies
Date: October 12, 2018
Request ID: S1807
Aim 1: Use targeted mass spectrometry to design assays measuring tau isoforms in human plasma.
Aim 2: Assess the plasma tau assay’s accuracy for predicting CSF amyloid beta status (positive/negative) and amyloid PET status (positive/negative).
Investigator: Stephanie Schultz
Project Title: Physical Activity and Brain Metabolism Across Adulthood and Disease
Date: September 19, 2018
Request ID: S1806
Aim 1: Identify physical activity characteristics that are associated with a �beneficial� brain metabolism biomarker profile in aging and AD
Aim 2: Assess both direct and indirect effects of physical activity on cognitive functioning while accounting for participants� levels of global or regional AG (mediator)
Investigator: Jonathan Peelle & Mitch Sommers
Project Title: Hearing and speech in Alzheimer�s Disease
Date: June 16, 2018
Request ID: S1805
Aim 1: Validate a short hearing test using test-retest reliability in participants with CDRs of 0, 0.5, and 1
Aim 2: Conduct exploratory analyses between hearing, cognitive, and imaging data to support future grant applications
Investigator: Lilah Besser
Project Title: Longitudinal associations between neighborhood greenspace and brain aging in non-demented older adults
Date: June 4, 2018
Request ID: S1804
Aim 1: Examine associations between baseline neighborhood greenspace and cognitive decline in non-demented older adults, and whether these associations vary by a) race/ethnicity; and b) APOE genotype.
Aim 2: Investigate if baseline neighborhood greenspace is associated with hippocampal and white matter hyperintensity volume in non-demented older adults, and whether these associations vary by a) race/ethnicity; and b) APOE genotype.
Aim 3: Examine association between change in neighborhood greenspace over time and a) cognitive decline; b) hippocampal volume; and c) white matter hyperintensity volume.
Investigator: Stark, Susan and Ances, Beau
Project Title: Falls: a marker of preclinical Alzheimer’s disease
Date: June 4, 2018
Request ID: S1803
Aim 1: To examine the relationship between falls and functional mobility in preclinical stages of AD
Aim 2: To examine a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.